PMID- 22826790
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 2036-3613 (Electronic)
IS  - 2036-3605 (Print)
IS  - 2036-3605 (Linking)
VI  - 4
IP  - 2
DP  - 2012 Apr 12
TI  - Unexpectedly durable palliation of metastatic olfactory neuroblastoma using 
      anti-angiogenic therapy with Bevacizumab.
PG  - e33
LID - 10.4081/rt.2012.e33 [doi]
LID - e33
AB  - Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from 
      olfactory epithelium and typically present with symptoms attributable to locally 
      invasive disease. Kadish radiographic staging and Hyams' histopathologic grading 
      are prognostic. Overall survival rates, averaging 60-70% at 5 years, remain 
      limited by high rates of delayed loco-regional and distant progression. At 
      initial presentation, the available evidence supports the use of multimodality 
      therapy, historically surgery and radiation, to improve disease-free and overall 
      survival. At recurrence/progression, the available evidence supports the use of 
      therapy to improve disease control and symptoms (palliation), but patient 
      heterogeneity dictates individualization of modalities. Although the ideal use of 
      chemotherapy as a modality remains undefined, the available evidence supports it 
      use, historically platinum-based, for palliation. However, recent insights into 
      the molecular-genetic aberrations of ONBs, coupled with the emergence 
      chemotherapeutic agents capable of targeting such aberrations, suggest an 
      expanded role. The authors report a case of a 60 years-old man, heavily 
      pre-treated for metastatic ONB, presenting with profound central-nerve-system and 
      head-and-neck symptoms. He experienced unexpectedly durable palliation with 
      Bevacizumab anti-angiogenic therapy. Additionally, he experienced localized 
      palliation with an Ommaya reservoir. The authors review the literature regarding 
      historical and emerging therapies for ONB to emphasize the needs for 
      individualization and translational-clinical studies.
FAU - Dunbar, Erin M
AU  - Dunbar EM
AD  - Department of Neurosurgery, Preston A. Wells Jr., Center for Brain Tumor Therapy;
FAU - Pumphrey, Phyllis K
AU  - Pumphrey PK
FAU - Bidari, Sharat
AU  - Bidari S
LA  - eng
PT  - Case Reports
DEP - 20120612
PL  - England
TA  - Rare Tumors
JT  - Rare tumors
JID - 101526926
PMC - PMC3401161
OTO - NOTNLM
OT  - anti-angiogenic therapy
OT  - metastatic.
OT  - olfactory neuroblastoma
OT  - ommaya resevoir
OT  - palliation
COIS- Conflict of interests: the authors report no potential conflict of interests.
EDAT- 2012/07/25 06:00
MHDA- 2012/07/25 06:01
PMCR- 2012/06/12
CRDT- 2012/07/25 06:00
PHST- 2011/12/24 00:00 [received]
PHST- 2012/05/10 00:00 [revised]
PHST- 2012/05/15 00:00 [accepted]
PHST- 2012/07/25 06:00 [entrez]
PHST- 2012/07/25 06:00 [pubmed]
PHST- 2012/07/25 06:01 [medline]
PHST- 2012/06/12 00:00 [pmc-release]
AID - rt.2012.e33 [pii]
AID - 10.4081/rt.2012.e33 [doi]
PST - ppublish
SO  - Rare Tumors. 2012 Apr 12;4(2):e33. doi: 10.4081/rt.2012.e33. Epub 2012 Jun 12.